Biologics in severe asthma
Biologic therapies for severe asthma.
Key point
Biologic choice in adult severe asthma can be impacted by quality of life impairment, lung function, exacerbation frequency, oral corticosteroid use, endotype, biomarkers and comorbidities.
From: Biologic Management in Severe Asthma for Adults: An American College of Chest Physicians Clinical Practice Guideline (Chest, 2026 Feb) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 21, 25, 26, 19, 18.
New guidelines and consensus this year
- Position statement on the appropriate usage of biologic therapies for asthma in South AfricaAfr J Thorac Crit Care Med2026
- Severe Asthma in Children and Adolescents: an AWMF Guideline by the German Society for Pediatric PulmonologyKlin Padiatr2026 Mar
- Understanding disease burden, challenges in current treatment strategies and call for action for management of severe asthma in Asia: a position statement from Asian respiratory expertsFront Allergy2026
- Biologic Management in Severe Asthma for Adults: An American College of Chest Physicians Clinical Practice GuidelineChest2026 Feb
All papers from the last 12 months
615 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Benralizumab effectiveness in a real-world Portuguese severe eosinophilic asthma population: BETREAT studyPulmonology2026 DecPMID 42464760
- Beyond biomarkers: the role of clinical factors associated with biologic therapy response in severe asthmaAnn Med2026 DecPMID 41672447
- Remission in moderate-to-severe pediatric asthma: Definitions, assessment, prevalence, predictors, and outcomes-a scoping reviewJ Allergy Clin Immunol Glob2026 NovPMID 42861070
- Using Asthma Phenotypes and Endotypes to Guide Treatment in Pediatric AsthmaImmunol Allergy Clin North Am2026 NovPMID 42833742Review
- Identification of severe eosinophilic asthma in patients with chronic rhinosinusitis and nasal polyps who are awaiting sinus surgeryJ Allergy Clin Immunol Glob2026 NovPMID 42733480
- Study selection and translational NNTs in severe asthma and COPD: methodological considerationsEur J Intern Med2026 Oct 16PMID 42888116
- Emerging therapeutic strategies and clinical trials in severe asthma management: current evidence and future directionsExpert Opin Biol Ther2026 Oct 15PMID 42872730Review
- Second-line dupilumab after anti-IL5/Rα failure: remission rates and clinical outcomes in severe asthmaJ Allergy Clin Immunol Pract2026 Oct 14PMID 42874915
- Effectiveness of mepolizumab in patients switching from prior biologic treatments for severe asthma: a post hoc analysis of the NUCALA effectiveness study (NEST)J Asthma2026 Oct 13PMID 42752293
- Valutazione clinico-economica di strategie integrate per la gestione dell’asma grave in Italia: un approccio predittivo multidimensionaleGlob Reg Health Technol Assess2026 Jan-DecPMID 42877782
More pulmonology trends
All specialties →Bronchiectasis
Non-cystic fibrosis bronchiectasis and its newer treatments.
Robotic and navigational bronchoscopy
Robotic and navigation bronchoscopy to biopsy peripheral lung nodules.
Antifibrotics in pulmonary fibrosis
Nintedanib, pirfenidone and newer antifibrotics.
Lung cancer screening
Low-dose CT screening for lung cancer.
Key point: Low-dose CT screening reduces lung cancer death risk by at least 21% and should be offered to people aged 50–75 with at least 20 pack-years.
E-cigarettes and the lungs
Respiratory effects of vaping and e-cigarettes.
Sotatercept
An activin signalling inhibitor for pulmonary arterial hypertension.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
"severe asthma"[tiab] AND (biologic*[tiab] OR tezepelumab[tiab] OR dupilumab[tiab] OR mepolizumab[tiab] OR benralizumab[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.